A Phase 3 interventional study of CC-5013 and Dexamethasone in Multiple Myeloma, sponsored by Celgene. Completed at 49 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-19.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 381 studies testing dexamethasone in Multiple Myeloma — 44 open to participants now, 104 under way, 14 of them phase 3. Dexamethasone · Multiple Myeloma.
Among the 381 studies testing dexamethasone in Multiple Myeloma, this one is the 28th largest by enrollment of the 373 interventional ones that give a count, is one of 9 that started in 2003, is one of 53 in phase 3, and was the 15th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →44 of the 381 studies testing dexamethasone in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Natalie Callander · Sites in United States
Ages 18+
AbbVie · Sites in United States, France, Japan and 1 more country
Ages 18+
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
University of Miami · Sites in United States
Ages 18+
Tanta University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
381 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 94 · Phase 2 273 · Phase 3 57 · Phase 4 9
First in 1995; this study’s year is marked. 9 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 353 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 45 across the 373 interventional studies. Of the 225 that completed or were terminated, 118 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
89 of 381 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
149 studies in Multiple Myeloma by Bristol-Myers Squibb: 9 open now, 18 under way, 6 of them phase 3. Of 120 finished, 43 (36%) have results posted.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 21st largest by enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2003, is one of 30 in phase 3, and was the 3rd registered.
Bristol-Myers Squibb’s Multiple Myeloma studies by the year they started, since 2001.
27 of the studies testing dexamethasone in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00572169Phase 3University of ArkansasUARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy | 2027-08 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04973605BeOne MedicinesA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | 2026-11 |
| NCT05560399Icahn School of Medicine at Mount SinaiA Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | 2026-11 |
Add all 27 to your calendar (.ics) → With an account.
Among the 381 studies testing dexamethasone in Multiple Myeloma, from their registry updates:
Among Bristol-Myers Squibb’s 149 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase.
This was a phase 3, multicenter, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of CC-5013 plus oral pulse high-dose dexamethasone and oral pulse high-dose dexamethasone therapy alone in subjects with relapsed or refractory multiple myeloma. Eligible subjects were randomized in a 1:1 ratio to 1 of 2 treatment groups: Subjects in the CC-5013/Dex treatment group took 25 mg of CC-5013 orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle; Subjects in the Placebo/Dex treatment group took 1 placebo capsule on Days 1 to 28 of each 28-day cycle. Subjects in both treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CC-5013 (lenalidomide) plus oral high-dose dexamethasone
Drug: CC-5013 · Drug: Dexamethasone
Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone
Drug: Dexamethasone
Subjects in the CC-5013/Dex treatment group took 25 mg of lenalidomide orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle.
Also known as: lenalidomide, Revlimid
Subjects in the CC-5013/Dex and Placebo/Dex treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.
Also known as: Decadron
Time to Tumor Progression (TTP)
Time to progression (TTP) was calculated as the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Bladé et. al., Br J Haematol 1998; 102:1115-1123.
Time frame: 60 weeks (median Time To Progression of CC-5013/Dex treatment group)
Overall Survival
Overall survival was calculated as the time from randomization to death from any cause.
Time frame: 170 weeks (median overall survival of CC-5013/Dex treatment group)
Myeloma Response
The overall confirmed response that was maintained for ≥6 weeks. Complete Response (CR):Disappearance of monoclonal paraprotein. Remission Response (RR):75-99% reduction in monoclonal paraprotein/90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR):50-74% reduction in monoclonal paraprotein/50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD):Criteria for PR or PD not met. Plateau Phase:If PR, stable monoclonal paraprotein (within 25% above or below nadir)/stable soft tissue plasmacytomas. Progressive Disease (PD):Disease worsens.
Time frame: Up to Unblinding (07 Jun 2005)
Time to First Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status Scale (Best Score=0, Fully Active, Able to Carry on All Pre-disease Performance Without Restriction; Worst Score=5, Dead.)
The time to first worsening on the ECOG Performance Scale was calculated as the time from randomization to the date of the first worsening compared to the last ECOG evaluation obtained prior to randomization.
Time frame: 30 weeks (mean time to first worsening of ECOG performance status for CC-5013/Dex treatment group)
Subjects in the Placebo/Dex treatment group did not continue participation beyond the period "Up To Unblinding (07 Jun 2005"). Only subjects in the CC-5013/Dex treatment group participated in the period "Extended Follow-up Cutoff (23 Jul 2008)".
| Milestone | CC-5013/Dex | Placebo/Dex |
|---|---|---|
| Started | 177 | 176 |
| Completed | 64 | 13 |
| Not completed | 113 | 163 |
| Withdrew: Adverse event | 35 | 18 |
| Withdrew: Progression of disease | 57 | 124 |
| Withdrew: Lack of efficacy | 3 | 5 |
| Withdrew: Withdrawal by subject | 8 | 8 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Other | 8 | 7 |
| Milestone | CC-5013/Dex | Placebo/Dex |
|---|---|---|
| Started | 177 | 0 |
| Completed | 6 | 0 |
| Not completed | 171 | 0 |
| Withdrew: Adverse event | 44 | 0 |
| Withdrew: Progression of disease | 87 | 0 |
| Withdrew: Lack of efficacy | 3 | 0 |
| Withdrew: Withdrawal by subject | 11 | 0 |
| Withdrew: Death | 5 | 0 |
| Withdrew: Other | 21 | 0 |
| Milestone | CC-5013/Dex | Placebo/Dex |
|---|---|---|
| Started | 6 | 0 |
| Completed | 0 | 0 |
| Not completed | 6 | 0 |
| Withdrew: Transferred into expanded access study. | 3 | 0 |
| Withdrew: Transferred into revassist program | 2 | 0 |
| Withdrew: Adverse event | 1 | 0 |
Time to progression (TTP) was calculated as the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Bladé et. al., Br J Haematol 1998; 102:1115-1123.
| Weeks | CC-5013/Dex | Placebo/Dex |
|---|---|---|
| Time to Tumor Progression (TTP) | 60.1 (41.1 to 80.0) | 20.1 (16.1 to 21.1) |
Overall survival was calculated as the time from randomization to death from any cause.
| Weeks | CC-5013/Dex | Placebo/Dex |
|---|---|---|
| Overall Survival | 170.1 (142.1 to 204.9) | 136.4 (104.1 to 176.9) |
The overall confirmed response that was maintained for ≥6 weeks. Complete Response (CR):Disappearance of monoclonal paraprotein. Remission Response (RR):75-99% reduction in monoclonal paraprotein/90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR):50-74% reduction in monoclonal paraprotein/50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD):Criteria for PR or PD not met. Plateau Phase:If PR, stable monoclonal paraprotein (within 25% above or below nadir)/stable soft tissue plasmacytomas. Progressive Disease (PD):Disease worsens.
| Participants | CC-5013/Dex | Placebo/Dex |
|---|---|---|
| Myeloma Response | 107 | 34 |
The time to first worsening on the ECOG Performance Scale was calculated as the time from randomization to the date of the first worsening compared to the last ECOG evaluation obtained prior to randomization.
| Weeks | CC-5013/Dex | Placebo/Dex |
|---|---|---|
| Time to First Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status Scale (Best Score=0, Fully Active, Able to Carry on All Pre-disease Performance Without Restriction; Worst Score=5, Dead.) | 29.9 ± 30.02 | 15.0 ± 16.98 |
Collected over Up to 254 weeks (median=48 weeks; mean=77 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CC-5013/Dex | — | 111/177 (62.7%) | 177/177 (100%) |
| Placebo/Dex | — | 90/175 (51.4%) | 175/175 (100%) |
| Event | CC-5013/Dex | Placebo/Dex |
|---|---|---|
| PNEUMONIAInfections and infestations | 30/177 | 15/175 |
| DEEP VEIN THROMBOSISVascular disorders | 18/177 | 6/175 |
| ATRIAL FIBRILLATIONCardiac disorders | 10/177 | 1/175 |
| DEHYDRATIONMetabolism and nutrition disorders | 7/177 | 5/175 |
| PYREXIAGeneral disorders | 7/177 | 6/175 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 6/177 | 1/175 |
| HYPERCALCAEMIAMetabolism and nutrition disorders | 2/177 | 5/175 |
| RENAL FAILURERenal and urinary disorders | 3/177 | 5/175 |
| CEREBROVASCULAR ACCIDENTNervous system disorders | 5/177 | 1/175 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 5/177 | 0/175 |
| Event | CC-5013/Dex | Placebo/Dex |
|---|---|---|
| FATIGUEGeneral disorders | 114/177 | 105/175 |
| NEUTROPENIABlood and lymphatic system disorders | 87/177 | 12/175 |
| DIARRHOEAGastrointestinal disorders | 85/177 | 53/175 |
| INSOMNIAPsychiatric disorders | 84/177 | 70/175 |
| CONSTIPATIONGastrointestinal disorders | 74/177 | 35/175 |
| ANAEMIABlood and lymphatic system disorders | 72/177 | 37/175 |
| MUSCLE CRAMPMusculoskeletal and connective tissue disorders | 69/177 | 41/175 |
| UPPER RESPIRATORY TRACT INFECTIONRespiratory, thoracic and mediastinal disorders | 63/177 | 39/175 |
| NAUSEAGastrointestinal disorders | 58/177 | 55/175 |
| OEDEMA PERIPHERALGeneral disorders | 58/177 | 42/175 |
| Age, Categorical(Participants) | CC-5013/Dex | Placebo/Dex | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 94 | 103 | 197 |
| >=65 years | 83 | 73 | 156 |
| Age, Continuous(years) | CC-5013/Dex | Placebo/Dex | Total |
|---|---|---|---|
| Mean | 63.3 ± 9.84 | 62.5 ± 9.81 | 62.9 ± 9.81 |
| Sex: Female, Male(Participants) | CC-5013/Dex | Placebo/Dex | Total |
|---|---|---|---|
| Female | 71 | 72 | 143 |
| Male | 106 | 104 | 210 |
| Region of Enrollment(participants) | CC-5013/Dex | Placebo/Dex | Total |
|---|---|---|---|
| United States | 142 | 150 | 292 |
| Canada | 35 | 26 | 61 |
Ran from Jan 2003 to primary completion in Nov 2005, 34 months.
Results were first posted in Mar 2010, 4 years 4 months after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 34 months is below that.
Counting every sponsor, half of 180 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone